Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.93
+0.21003.67%
Post-market: 5.930.00000.00%16:04 EDT
Volume:251.31K
Turnover:1.46M
Market Cap:334.65M
PE:-3.16
High:5.96
Open:5.72
Low:5.58
Close:5.72
Loading ...

Astria Therapeutics Q1 Operating Expenses USD 36.995 Million

THOMSON REUTERS
·
14 May

Press Release: Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
14 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
05 May

Astria Therapeutics Announces New Stock Option Grants Under 2022 Inducement Plan for New Employees

Reuters
·
03 May

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 May

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Business Wire
·
01 May

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Business Wire
·
30 Apr

Astria Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

Top Premarket Decliners

MT Newswires Live
·
21 Apr

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)

TIPRANKS
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
05 Mar

Astria Therapeutics Price Target Maintained With a $26.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

TD Cowen Remains a Buy on Astria Therapeutics (ATXS)

TIPRANKS
·
02 Mar

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)

TIPRANKS
·
28 Feb